At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared to 23.6% of patients treated with ipilimumab RAHWAY, N.J., September 15, ...

The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Please see Prescribing Information for KEYTRUDA (pembrolizumab ...

RAHWAY, N.J., August 29, 2024--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today provided updates on two Phase 3 trials, KEYNOTE-867 and KEYNOTE-630.

Overall survival (OS) data for KEYTRUDA ® (pembrolizumab) in earlier stages of women’s cancers, including high-risk early-stage triple-negative breast cancer (KEYNOTE-522) and high-risk locally ...

Pembrolizumab plus chemoradiotherapy improved survival in patients with previously untreated, high-risk locally advanced ...

Pfizer and Astellas have a clinical collaboration agreement with Merck to evaluate the combination of PADCEV ® and KEYTRUDA ® in patients with previously untreated metastatic urothelial cancer.

PI was held by 29 hedge funds in Q2 2024 ... The results show that ivonescimab is better off than the current standard drug Keytruda from Merck. Ivonescimab is a bispecific antibody, meaning ...

The S&P 500's 2024 rally continued in July as second-quarter GDP growth numbers exceeded expectations. Investors also expect Federal Reserve rate cuts are now just around the corner. The S& ...

Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing authorization of mirvetuximab soravtansine (ELAHERE®) for the ...